Сравнительная оценка выживаемости больных раком предстательной железы. Современный взгляд на проблему
Актуальные проблемы
Дата публикации: декабря 19, 2014
Ключевые слова
рак простаты
ракоспецифичная выживаемость
ракоспецифичная выживаемость
Как цитировать
Дарий Е., Бедретдинова Д., Гарманова Т. Сравнительная оценка выживаемости больных раком предстательной железы. Современный взгляд на проблему // Кремлевская медицина. Клинический вестник. 2014. Т. № 3. С. 13-17.
Аннотация
Проведен анализ выживаемости 291 больного раком предстательной железы (РПЖ), длительно наблюдавшегосяв поликлинике. Оценивалось значение РПЖ как причины смерти пациентов с данным заболеванием. Установлено, чторакоспецифичная выживаемость и выживаемость по другим заболеваниям у пациентов с диагностированным РПЖ неразличаются. В возрасте 50–59 лет наблюдается более агрессивное течение РПЖ, который часто становится причинойсмерти, тогда как большая часть пациентов 80 лет и старше умирает от других заболеваний. Авторы обсуждают выборметода лечения в каждой возрастной группе с учетом общего соматического статуса пациента, а также особенностиведения пациентов с клинически незначимым РПЖ в возрасте старше 80 лет.Ключевые слова: рак простаты, ракоспецифичная выживаемость.A survival analysis has been done for 291 patients with prostatic cancer who were followed-up in a polyclinic unit fora long period of time. In the present study the authors have evaluated the importance of prostatic cancer as a death cause inpatients with prostatic cancer. It has been found out that patients with diagnosed prostatic cancer had the same level of survivalfor cancer as well as for other accompanying diseases. In patients aged 50–59 prostatic cancer has more aggressive courseand often becomes the cause of their death, while patients aged 80 and older die of other reasons. The authors also discuss achoice of curative techniques for each age group depending on patient’s somatic status. They also discuss peculiarities of carein patients older than 80 with clinically nonsignificant prostatic cancer.Кey words: prostatic cancer, cancer-specific survival.Литература
1. Maximum androgen blockade in advanced prostate cancer:
an overview of the randomised trials. Prostate Cancer Trialists’
Collaborative Group // Lancet. — 2000. — Vol. 355. — P. 1491–
1498.
2. Capitanio U., Jeldres C., Shariat S.F., Karakiewicz P.
Clinicians are most familiar with nomograms and rate their clinical
usefulness highest, look-up tables are second best // Eur Urol. —
2008. — Vol. 54. — P. 958–959.
3. Catalona W.J., Partin A.W., Slawin K.M. et al. Use of the
percentage of free prostate-specific antigen to enhance differentiation
of prostate cancer from benign prostatic disease: a prospective
multicenter clinical trial // Jama. — 1998. — Vol. 279. — P. 1542–
1547.
4. Chun F.K., Haese A., Ahyai S.A. et al. Critical assessment
of tools to predict clinically insignificant prostate cancer at radical
prostatectomy in contemporary men // Cancer. — 2008. — Vol. 113.
— P. 701–709.
5. D’Amico A.V., Chen M.H., Roehl K.A., Catalona W.J.
Preoperative PSA velocity and the risk of death from prostate cancer
after radical prostatectomy // N Engl J Med. — 2004. — Vol. 351.
— P. 125–135.
6. D’Amico A.V., Cote K., Loffredo M. et al. Determinants of
prostate cancer-specific survival after radiation therapy for patients
with clinically localized prostate cancer // J Clin Oncol. — 2002.
— Vol. 20. — P. 4567–4573.
7. Dall’Era M.A., Cooperberg M.R., Chan J.M. et al. Active
surveillance for early-stage prostate cancer: review of the current
literature // Cancer. — 2008. — Vol. 112. — P. 1650–1659.
8. Epstein J.I. Pathology of prostatic intraepithelial neoplasia
and adenocarcinoma of the prostate: prognostic influences of stage,
tumor volume, grade, and margins of resection // Semin Oncol. —
1994. — Vol. 21. — P. 527–541.
9. Epstein J. I., Walsh P. C., Carmichael M., Brendler C. B.
Pathologic and clinical findings to predict tumor extent of nonpalpable
(stage T1c) prostate cancer // Jama. — 1994. — Vol. 271. — P.
368–374.
10. Etzioni R., Penson D.F., Legler J.M. et al. Overdiagnosis
due to prostate-specific antigen screening: lessons from U.S. prostate
cancer incidence trends // J Natl Cancer Inst. — 2002. — Vol. 94.
— P. 981–990.
11. Ferlay J., Autier P., Boniol M. et al. Estimates of the cancer
incidence and mortality in Europe in 2006 // Ann Oncol. — 2007.
— Vol. 18. — P. 581–592.
12. Heidenreich A., Aus G., Bolla M. et al. EAU guidelines on
prostate cancer // Eur Urol. — 2008. — Vol. 53. — P. 68–80.
13. Heidenreich A., Aus G., Bolla M. et al. [EAU guidelines
on prostate cancer] // Actas Urol Esp. — 2009. — Vol. 33. — P.
113–126.
14. Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2009 //
CA Cancer J Clin. — 2009. — Vol. 59. — P. 225–249.
15. Johansson J. E., Andren O., Andersson S. O. et al. Natural
history of early, localized prostate cancer // Jama. — 2004. — Vol.
291. — P. 2713–2719.
16. Kattan M. W., Eastham J. A., Wheeler T. M. et al.
Counseling men with prostate cancer: a nomogram for predicting the
presence of small, moderately differentiated, confined tumors // J
Urol. — 2003. — Vol. 170. — P. 1792–1797.
17. Makarov D.V., Trock B.J., Humphreys E.B. et al. Updated
nomogram to predict pathologic stage of prostate cancer given
prostate-specific antigen level, clinical stage, and biopsy Gleason
score (Partin tables) based on cases from 2000 to 2005 // Urology.
— 2007. — Vol. 69. — P. 1095–1101.
18. Patel M.I., DeConcini D.T., Lopez-Corona E. et al.
An analysis of men with clinically localized prostate cancer who
deferred definitive therapy // J Urol. — 2004. — Vol. 171. — P.
1520–1524.
19. Sakr W.A., Grignon D.J., Crissman J.D. et al. High
grade prostatic intraepithelial neoplasia (HGPIN) and prostatic
adenocarcinoma between the ages of 20–69: an autopsy study of 249
cases // In Vivo. — 1994. — Vol. 8. — P. 439–443.
20. Sanda M.G., Dunn R.L., Michalski J. et al. Quality of life
and satisfaction with outcome among prostate-cancer survivors // N
Engl J Med. — 2008. — Vol. 358. — P. 1250–1261.
21. Schroder F.H., Carter H.B., Wolters T. et al. Early detection
of prostate cancer in 2007. Part 1: PSA and PSA kinetics // Eur
Urol. — 2008. — Vol. 53. — P. 468–477.
И др. авторы.
an overview of the randomised trials. Prostate Cancer Trialists’
Collaborative Group // Lancet. — 2000. — Vol. 355. — P. 1491–
1498.
2. Capitanio U., Jeldres C., Shariat S.F., Karakiewicz P.
Clinicians are most familiar with nomograms and rate their clinical
usefulness highest, look-up tables are second best // Eur Urol. —
2008. — Vol. 54. — P. 958–959.
3. Catalona W.J., Partin A.W., Slawin K.M. et al. Use of the
percentage of free prostate-specific antigen to enhance differentiation
of prostate cancer from benign prostatic disease: a prospective
multicenter clinical trial // Jama. — 1998. — Vol. 279. — P. 1542–
1547.
4. Chun F.K., Haese A., Ahyai S.A. et al. Critical assessment
of tools to predict clinically insignificant prostate cancer at radical
prostatectomy in contemporary men // Cancer. — 2008. — Vol. 113.
— P. 701–709.
5. D’Amico A.V., Chen M.H., Roehl K.A., Catalona W.J.
Preoperative PSA velocity and the risk of death from prostate cancer
after radical prostatectomy // N Engl J Med. — 2004. — Vol. 351.
— P. 125–135.
6. D’Amico A.V., Cote K., Loffredo M. et al. Determinants of
prostate cancer-specific survival after radiation therapy for patients
with clinically localized prostate cancer // J Clin Oncol. — 2002.
— Vol. 20. — P. 4567–4573.
7. Dall’Era M.A., Cooperberg M.R., Chan J.M. et al. Active
surveillance for early-stage prostate cancer: review of the current
literature // Cancer. — 2008. — Vol. 112. — P. 1650–1659.
8. Epstein J.I. Pathology of prostatic intraepithelial neoplasia
and adenocarcinoma of the prostate: prognostic influences of stage,
tumor volume, grade, and margins of resection // Semin Oncol. —
1994. — Vol. 21. — P. 527–541.
9. Epstein J. I., Walsh P. C., Carmichael M., Brendler C. B.
Pathologic and clinical findings to predict tumor extent of nonpalpable
(stage T1c) prostate cancer // Jama. — 1994. — Vol. 271. — P.
368–374.
10. Etzioni R., Penson D.F., Legler J.M. et al. Overdiagnosis
due to prostate-specific antigen screening: lessons from U.S. prostate
cancer incidence trends // J Natl Cancer Inst. — 2002. — Vol. 94.
— P. 981–990.
11. Ferlay J., Autier P., Boniol M. et al. Estimates of the cancer
incidence and mortality in Europe in 2006 // Ann Oncol. — 2007.
— Vol. 18. — P. 581–592.
12. Heidenreich A., Aus G., Bolla M. et al. EAU guidelines on
prostate cancer // Eur Urol. — 2008. — Vol. 53. — P. 68–80.
13. Heidenreich A., Aus G., Bolla M. et al. [EAU guidelines
on prostate cancer] // Actas Urol Esp. — 2009. — Vol. 33. — P.
113–126.
14. Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2009 //
CA Cancer J Clin. — 2009. — Vol. 59. — P. 225–249.
15. Johansson J. E., Andren O., Andersson S. O. et al. Natural
history of early, localized prostate cancer // Jama. — 2004. — Vol.
291. — P. 2713–2719.
16. Kattan M. W., Eastham J. A., Wheeler T. M. et al.
Counseling men with prostate cancer: a nomogram for predicting the
presence of small, moderately differentiated, confined tumors // J
Urol. — 2003. — Vol. 170. — P. 1792–1797.
17. Makarov D.V., Trock B.J., Humphreys E.B. et al. Updated
nomogram to predict pathologic stage of prostate cancer given
prostate-specific antigen level, clinical stage, and biopsy Gleason
score (Partin tables) based on cases from 2000 to 2005 // Urology.
— 2007. — Vol. 69. — P. 1095–1101.
18. Patel M.I., DeConcini D.T., Lopez-Corona E. et al.
An analysis of men with clinically localized prostate cancer who
deferred definitive therapy // J Urol. — 2004. — Vol. 171. — P.
1520–1524.
19. Sakr W.A., Grignon D.J., Crissman J.D. et al. High
grade prostatic intraepithelial neoplasia (HGPIN) and prostatic
adenocarcinoma between the ages of 20–69: an autopsy study of 249
cases // In Vivo. — 1994. — Vol. 8. — P. 439–443.
20. Sanda M.G., Dunn R.L., Michalski J. et al. Quality of life
and satisfaction with outcome among prostate-cancer survivors // N
Engl J Med. — 2008. — Vol. 358. — P. 1250–1261.
21. Schroder F.H., Carter H.B., Wolters T. et al. Early detection
of prostate cancer in 2007. Part 1: PSA and PSA kinetics // Eur
Urol. — 2008. — Vol. 53. — P. 468–477.
И др. авторы.